Skip to main content

Table 1 Patient characteristics based on timing of plain transversus abdominis plane (TAP) block

From: Effect of preoperative versus postoperative use of transversus abdominis plane block with plain 0.25 % bupivacaine on postoperative opioid use: a retrospective study

Variables Overall
(N = 262)
Preoperative TAP
(n = 240)
Postoperative TAP
(n = 22)
P-value
Age, years, mean (SD) 57.76 (16.10) 57.83 (15.87) 56.95 (18.90) 0.807
Male, no. (%) 118 (45.0) 107 (44.6) 11 (50.0) 0.791
Body mass index, kg/m2, mean (SD) 28.38 (7.32) 28.51 (7.48) 27.03 (5.27) 0.366
Diabetes mellitus, no. (%) 67 (25.6) 64 (26.7) 3 (13.6) 0.278
Hyperlipidemia, no. (%) 156 (59.5) 144 (60.0) 12 (54.5) 0.786
Cigarette smoking, no. (%) 85 (32.4) 80 (33.3) 5 (22.7) 0.436
History of COPD, no. (%) 21 (8.0) 19 (7.9) 2 (9.1) 0.692
Alcohol use, no. (%) 126 (48.1) 113 (47.1) 13 (59.1) 0.392
Hypertension, no. (%) 132 (50.4) 121 (50.4) 11 (50.0) 0.99
History of CHF, no. (%) 22 (8.4) 21 (8.8) 1 (4.5) 0.705
Current opioid use, no. (%) 43 (16.5) 41 (17.2) 2 (9.1) 0.499
Steroid use, no. (%) 37 (14.1) 31 (12.9) 6 (27.3) 0.126
Previous abdominal surgery, no. (%) 170 (64.9) 157 (65.4) 13 (59.1) 0.718
Blood thinner use, no. (%)
 Aspirin 52 (19.8) 47 (19.6) 5 (22.7) 0.941
 Warfarin 7 (2.7) 6 (2.5) 1 (4.5) 0.463
 Plavix 11 (4.2) 11 (4.6) 0 (0.0) 0.607
 Others 25 (9.5) 22 (9.2) 3 (13.6) 0.451
ASA class, no. (%)   0.241
 ASA class 1 1 (0.4) 1 (0.4) 0 (0.0)  
 ASA class 2 85 (32.4) 78 (32.5) 7 (31.8)
 ASA class 3 169 (64.5) 156 (65.0) 13 (59.1)
 ASA class 4 7 (2.7) 5 (2.1) 2 (9.1)
 ASA > 2 176 (67.2) 161 (67.1) 15 (68.2) 0.99
Surgical indication, no. (%)
 Malignancy 129 (49.2) 119 (49.6) 10 (45.5) 0.882
 IBD 52 (19.8) 46 (19.2) 6 (27.3) 0.401
 Benign disease 128 (48.9) 116 (48.3) 12 (54.5) 0.738
  1. ASA American Society of Anesthesiology, COPD chronic obstructive pulmonary disease, CHF congestive heart failure, IBD inflammatory bowel disease, SD standard deviation